Skip to main content
. Author manuscript; available in PMC: 2023 Mar 17.
Published in final edited form as: J Alzheimers Dis. 2017;56(1):335–349. doi: 10.3233/JAD-160916

Fig. 2.

Fig. 2.

Reduction in cdk5 activity post TFP5 treatment. A) Autoradiograph of kinase assays in brain lysates derived from WT control and p25 non-expressing transgenics compared to those from p25 expressing mutants with and without TFP5 treatment (i.e., scrambled peptide, S). B) Quantitation of pad assays of cdk5 kinase activities in brain lysates derived from identical cohorts as in A. TFP5 treatment produces a significant reduction in activity (compare lanes 2, 3, 4) while scrambled peptide treatment (lane 5) has no effect. (n = 4; *p < 0.05, **p < 0.01).